Renata PLC, a pharmaceutical company listed on the stock exchanges, has received regulatory approval to market its Levothyroxine Sodium Tablets in six European Union countries under the EU’s Decentralised Procedure (DCP).

According to a disclosure published through the Dhaka Stock Exchange (DSE), the approval covers Ireland, Germany, Italy, Poland, Portugal, and Malta.

The company said the tablets will be manufactured at its EU Good Manufacturing Practice (EU GMP)-approved potent product manufacturing facility, ensuring compliance with European quality standards.

Renata also said it is committed to ensuring a safe and reliable supply of Levothyroxine in the newly approved EU markets and will provide the necessary support to facilitate product availability.

The approval marks another step in the company’s efforts to expand its international pharmaceutical footprint, particularly in regulated European markets.